Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 472 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Testing Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers

NCT03473184
View directory record Official record
Conditions
Healthy
Interventions
Diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Phase 1 Interventional

Multiple Antigen-Engineered DC Vaccine for Melanoma

NCT01622933
View directory record Official record
Conditions
Melanoma
Interventions
DC Vaccine + IFN, AdVTMM2/DC Vaccination
Biological
Lead sponsor
Lisa H. Butterfield, Ph.D.
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 21, 2026, 1:17 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT04491942
View directory record Official record
Conditions
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Cisplatin, Elimusertib, Gemcitabine Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Sacramento, California • Bethesda, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Phase 2 Interventional

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

NCT00258635
View directory record Official record
Conditions
Type I Hypersensitivity
Interventions
RagweedMATAMPL
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Novi, Michigan • Minneapolis, Minnesota • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 21, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

NCT05130606
View directory record Official record
Conditions
Hereditary Breast and Ovarian Cancer
Interventions
Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.", FORCE Fact Sheet
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
332 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Skin Testing Reagents for Penicillin Allergy

NCT01818336
View directory record Official record
Conditions
History of IgE Dependent Reaction to a Penicillin Product
Interventions
Penicillin skin test kit
Drug
Lead sponsor
AllerQuest LLC
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 21, 2026, 1:17 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

NCT02194387
View directory record Official record
Conditions
Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
Interventions
Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention
Dietary Supplement · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Not listed No phase listed Observational

Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)

NCT05845593
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Decision Support Test
Other
Lead sponsor
Ampel BioSolutions, LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

NCT02737631
View directory record Official record
Conditions
Erythema, Edema
Interventions
"Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 21, 2026, 1:17 AM EDT
Completed No phase listed Observational

Minoxidil Response Testing in Males With Androgenetic Alopecia

NCT02198261
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% minoxidil topical foam
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 21, 2026, 1:17 AM EDT
Completed No phase listed Observational

A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer

NCT02888366
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Menssana Research, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Montclair, New Jersey • Newark, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 21, 2026, 1:17 AM EDT
Withdrawn Phase 1 Interventional

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

NCT04500548
View directory record Official record
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Primary Central Nervous System Neoplasm, Xeroderma Pigmentosum
Interventions
Biospecimen Collection, Ipilimumab, Nivolumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Withdrawn No phase listed Observational

Validation of a Molecular Prognostic Test for Eye Melanoma

NCT00406120
View directory record Official record
Conditions
Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms
Interventions
Fine needle aspiration biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Not applicable Interventional

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer

NCT02400060
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage 0 Breast Cancer
Interventions
Telephone-Based Intervention, Survey Administration, Laboratory Biomarker Analysis
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Goldsboro, North Carolina • Winston-Salem, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 21, 2026, 1:17 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

NCT01989897
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol
Drug
Lead sponsor
Bryan Martin, DO
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 21, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional

Testing a Mammography Decision Intervention in a Rural Setting

NCT06522568
View directory record Official record
Conditions
Breast Cancer
Interventions
MyMammogram, Provider communication
Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
39 Years to 49 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Keene, New Hampshire • New London, New Hampshire • Newport, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Phase 1 Interventional Results available

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

NCT02595866
View directory record Official record
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 21, 2026, 1:17 AM EDT
Withdrawn Not applicable Interventional

Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease

NCT00312637
View directory record Official record
Conditions
Breast Cancer
Interventions
Magnetic Resonance Spectroscopy
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Performance Testing of Philips FAST SpO2 With Masimo Pulse Oximetry Sensors Across Skin Pigmentation

NCT06148623
View directory record Official record
Conditions
Healthy
Interventions
Philips FAST SpO2 with Masimo Pulse Oximetry Sensors
Device
Lead sponsor
Masimo Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

NCT05131477
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 1:17 AM EDT
Terminated Phase 2Phase 3 Interventional

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

NCT05747794
View directory record Official record
Conditions
Breast Carcinoma
Interventions
eftilagimod alpha, Paclitaxel, placebo
Biological · Drug · Other
Lead sponsor
Immutep S.A.S.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
43
States / cities
Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 1:17 AM EDT
Terminated Phase 2 Interventional

Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer

NCT02008994
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Genomic and Proteomic Profiling
Other
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 21, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis

NCT01012713
View directory record Official record
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Clobex Spray, Vectical Ointment, Excimer Laser
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 21, 2026, 1:17 AM EDT